• Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III




Thrombosis prevention



  • Program
  • Indication

CS1 in Phase II for the treatment of PAH

The drug candidate CS1 is a HDAC inhibitor with a new advanced reformulation of valproic acid (VPA) and acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic, and pressure-relieving properties. CS1 is being developed as a treatment for the rare disease PAH with the aim of offering patients a better and safer disease-modifying drug. CS1’s unique efficacy profile fits well with the pathogenetic mechanisms of the rare disease PAH and is believed to be able to address today’s major unmet need for better treatment alternatives.


Preclinical programs

Cereno has two preclinical programs that are being evaluated for the treatment of cardiovascular diseases; CS014 and CS585. The purpose is to conduct full preclinical development programs to meet the requirements to start clinical studies.

Scientific publications

Access scientific publications related to Cereno's pipeline.